Vaccination remains the best strategy for preventing COVID-19
Em março de 2022, o Brasil se juntou a uma lista crescente de nações ao autorizar o uso emergencial do Paxlovid, antiviral da Pfizer contra a COVID-19. A decisão da Anvisa, fruto de uma análise multidisciplinar rigorosa, reflete o esforço contínuo da humanidade em ampliar seu arsenal terapêutico diante de uma pandemia que ainda exige respostas em múltiplas frentes. A aprovação não representa uma virada de página, mas um acréscimo cuidadoso — mais uma ferramenta nas mãos dos médicos para tentar impedir que o adoecimento se torne tragédia.
- Com pacientes em risco de agravamento sem opções antivirais aprovadas no país, a pressão por alternativas terapêuticas era crescente no Brasil.
- A Pfizer submeteu o pedido em 15 de fevereiro, e a Anvisa concluiu sua análise em tempo recorde, sinalizando a urgência reconhecida pela própria agência.
- A aprovação é cercada de limites precisos: apenas adultos sem necessidade de oxigênio suplementar, por no máximo cinco dias, sem uso preventivo.
- Mulheres em idade fértil receberam alerta específico — ausência de dados em gestantes levou a agência a recomendar evitar gravidez durante e por sete dias após o tratamento.
- A diretora Meiruze Freitas foi direta ao antecipar equívocos: o Paxlovid não substitui a vacina, que segue como principal estratégia de prevenção.
Em março de 2022, a Anvisa aprovou o uso emergencial do Paxlovid, antiviral da Pfizer para tratamento da COVID-19 em adultos com risco de agravamento que ainda não necessitam de oxigênio suplementar. O pedido havia sido apresentado pela farmacêutica em 15 de fevereiro, e a decisão colocou o Brasil ao lado de países como Estados Unidos, Reino Unido, Canadá, China, Austrália, Japão e México, que já haviam autorizado o medicamento.
A diretora Meiruze Freitas destacou que a aprovação foi resultado de uma análise criteriosa conduzida por equipe multidisciplinar, que avaliou todas as evidências científicas disponíveis, ponderando riscos conhecidos e potenciais frente aos benefícios documentados. Longe de ser um atalho regulatório, a medida representou uma adição deliberada ao conjunto de opções terapêuticas disponíveis para médicos que buscam evitar hospitalizações.
A agência foi igualmente enfática quanto às restrições: o medicamento não é indicado para pacientes já hospitalizados com quadros graves ou críticos, não pode ser usado de forma preventiva e tem janela de tratamento limitada a cinco dias. Para mulheres em idade fértil, a recomendação foi evitar gravidez durante o tratamento e nos sete dias seguintes, dado que não há dados de segurança em gestantes.
Freitas também antecipou uma possível interpretação equivocada: a existência de um antiviral eficaz não diminui a importância da vacinação. As vacinas seguem como a principal estratégia para prevenir a doença, as hospitalizações e as mortes. O Paxlovid atua em outro momento — quando o vírus já está presente e o objetivo é impedir que o quadro piore. São respostas distintas para partes distintas do mesmo problema.
Brazil's health regulator gave the green light on March 30 to emergency use of Pfizer's Paxlovid, an antiviral treatment for COVID-19. The approval came after the pharmaceutical company submitted its request on February 15, and it clears the way for the drug to be used in adult patients who are not yet sick enough to need supplemental oxygen but face a genuine risk of their illness worsening into severe disease.
The medication was not new to the world. It had already secured emergency authorization in the United States, across Europe, Canada, China, Australia, Japan, the United Kingdom, and Mexico. Brazil's decision to approve it represented another nation joining a growing list of countries betting on the antiviral as part of their pandemic response toolkit.
Meiruze Freitas, the Anvisa director who oversaw the evaluation, emphasized that the agency had subjected Paxlovid to the full weight of its review process. A multidisciplinary team of public health officials had examined all available scientific evidence, she explained, weighing the known and potential risks against the documented benefits. The approval, she stressed, was not a shortcut but a deliberate addition to Brazil's arsenal of COVID-19 treatments—one more option among several for doctors trying to keep patients out of the hospital.
But the agency was equally clear about what Paxlovid could not do. It was not authorized for patients already hospitalized with severe or critical COVID-19. It could not be used as a preventive measure for people who had not yet contracted the virus. And the treatment window was narrow: five days maximum. The regulator also flagged a precaution for women of childbearing age. Because there was no safety data from pregnant women, the agency recommended avoiding pregnancy during treatment and for seven days after the final dose.
Freitas made a point that seemed to anticipate a question some might ask: Did this new treatment mean vaccination was less important? No, she said directly. Vaccination remained the best strategy for preventing COVID-19 altogether, for keeping people out of hospitals, and for preventing deaths. Paxlovid was not a replacement for that work. It was something else—a way to intervene once someone was already sick, to try to stop the disease from getting worse. The two approaches worked in different parts of the same problem.
Notable Quotes
Vaccination continues to be the best strategy to prevent COVID-19, hospitalizations, and deaths— Meiruze Freitas, Anvisa director
The Hearth Conversation Another angle on the story
Why did Brazil need to approve this separately if it was already authorized in eight other countries?
Because each country's health authority has to make its own judgment. Anvisa couldn't just accept another nation's decision—they had to review the evidence themselves, weigh the risks, and decide if it made sense for Brazilian patients and the Brazilian health system.
The approval seems narrow. Five days only, and only for people not yet hospitalized. Why such tight limits?
That's where the evidence was strongest. The clinical trials showed the drug worked best when given early, before someone got so sick they needed oxygen support. After five days, the benefit wasn't clear. And once you're hospitalized with severe COVID, the virus has already done a lot of damage—a five-day antiviral course probably can't help much at that point.
The director kept saying vaccination is still the best strategy. Did she seem worried people would stop getting vaccinated?
I think she was being precise about what each tool does. Vaccination prevents infection in the first place. Paxlovid treats infection that's already happening. They're not competitors—they're answers to different moments in the same disease.
What about the warning for pregnant women? That seems significant.
It is. They simply didn't have safety data. So rather than guess, they said don't use it in pregnancy and don't get pregnant while taking it. It's the cautious move when you don't know.
Does this change how doctors will treat COVID in Brazil?
It gives them another option, but only for a specific group—sick adults who aren't yet critical. For most people, it won't change anything. For that narrow group, it might prevent a hospital admission.